San Francisco—A multicenter research team has found that patients who underwent bunionectomy reported better pain relief with oliceridine (TRV130, Trevena), a novel mu-receptor G-protein pathway-selective modulator, than counterparts who received either placebo or morphine. Oliceridine differentially activates G-protein–mediated analgesia while causing low beta-arrestin–mediated adverse events.
“G-protein–coupled receptor signaling is involved in the mechanism of